Introduction {#S1}
============

Schizophrenia (SCZ) is a debilitating neurodevelopmental disorder with pathogenetic roots during development, much before the most prominent symptoms of psychosis appear in adolescence^[@R1],\ [@R2]^. Postmortem tissue studies^[@R3]--[@R5]^ and brain imaging^[@R6]--[@R9]^ provide a wealth of information on abnormalities in patient brains but are not suitable to study the molecular and cellular changes of early development. Peripheral cells have been used as a model for studying schizophrenia^[@R10]^, but it is not clear how informative these cells are, considering that a large portion of the pathogenesis mechanism could be specific to the nervous system. Lack of informative developmental tissues hampers understanding of the pathogenesis mechanism of SCZ. Based on the high heritability of SCZ^[@R11]^, iPSC technology^[@R12]^ can be used to generate disease-relevant developmental tissues and to study molecular and cellular abnormalities occurring during early development^[@R13]--[@R20]^, on the condition that well-defined and homogeneous populations of disease-relevant cell types can be consistently generated from iPSCs. Many iPSC-derived neurons used in SCZ studies have been mixed populations of different neuronal subtypes^[@R21]^, often with varying proportions of subtypes from batch to batch. Such heterogeneity can address some issues but could also have resulted in variability of culture composition, leading to missed or false differences, and an inability to in identify abnormalities of specific processes in specific cell types.

Numerous postmortem studies have shown that one of the most consistently affected neuronal types in SCZ patient brains are GABAergic cortical interneurons (cINs), especially parvalbumin (PV)^+^ or somatostatin (SST)^+^ expressing cINs^[@R22]--[@R24]^, derived from the medial ganglionic eminence (MGE). Functionally, it was suggested that altered GABA neurotransmission in SCZ results in abnormalities of gamma oscillation, thereby causing cognitive impairments in SCZ patients^[@R25]^. Accordingly, pharmacological activation of the GABA~A~ receptor restored gamma band activity in SCZ patients, accompanied by some degree of improved cognitive function^[@R26]^. However, conventional studies using postmortem brains or brain imaging were not able to distinguish whether there are intrinsic abnormalities in cINs that cause cIN hypofunction in SCZ brains, or whether cIN hypofunction is secondary to impaired glutamatergic input onto cINs, as also observed post mortem. Understanding cIN-specific pathogenetic mechanisms will help in the design of therapeutics that better treat/prevent SCZ, especially its cognitive deficits, which are not adequately responsive to current anti-psychotic treatments. Thus, with the aim of modeling cIN-intrinsic SCZ pathogenetic mechanisms without the presence of other neuronal subtypes, we developed an efficient method of generating a homogeneous population of MGE-derived developmental cINs from human pluripotent stem cells (hPSCs), as described in our previous studies^[@R27],\ [@R28]^.

Mitochondria are critically involved in various aspects of neuronal functions, including synaptic transmission^[@R29]--[@R32]^, Ca^2+^ signaling^[@R33],\ [@R34]^, generation of action potentials^[@R35]^ and ion homeostasis^[@R36]--[@R38]^, enabling these energy demanding processes. Thus, it is conceivable that hypofunction of mitochondria could result in suboptimal neuronal function in circuit environments^[@R39]--[@R41]^. In line with the notion of OxPhox deficits being causal in SCZ pathogenesis^[@R35]^, mitochondrial abnormalities caused by haploinsufficiency of Mrpl40 (one of the 22q11DS locus genes) resulted in SCZ-relevant behavioral deficits in mice^[@R42]^. Moreover, Cox10 deletion in Parvalbumin^+^ cINs results in abnormal gamma oscillations in the Prefrontal cortex (PFC) and hippocampus, accompanied by deficits in sensory motor gating and sociability^[@R43]^.

In well-defined homogeneous developmental cIN populations, we observed deficits in the OxPhos pathway as one of the major abnormalities in developing SCZ cINs. Mild but significant decreases in OxPhos gene expression levels were functionally translated to mitochondria hypofunction in developing SCZ cINs. This abnormality is intrinsic to cINs, in the absence of any other neuronal subtypes that could affect their functionality. Hypofunction of mitochondria resulted in oxidative stress in the cells, which was successfully reversed by treating the cells with ALA/ALC^[@R44]--[@R47]^, but not by most other chemicals tested. Reversal of mitochondrial hypofunction in SCZ cINs was accompanied by the restoration of other SCZ cIN abnormalities, such as arborization^[@R48]^. Unlike SCZ cINs, the OxPhos deficit was not observed in SCZ glutamatergic neurons. Determining this was only possible through the use of homogeneous populations of iPSC-derived neuronal subtypes. This novel understanding of the intrinsic abnormalities of developing SCZ cINs may help in the development of new therapeutics to better treat/prevent SCZ, and especially cIN-associated symptoms.

Results {#S2}
=======

Homogeneous populations of developmental cINs were generated from HC vs. SCZ iPSCs {#S3}
----------------------------------------------------------------------------------

As the first step in studying SCZ pathogenetic mechanisms in disease-relevant developmental tissues, we generated iPSCs from 9 HC vs. 9 SCZ fibroblast lines using modified RNA methods^[@R49]^. It is critical to use an integration-free reprogramming method to study SCZ, since SCZ is a disease with complex genetics where hundreds of genetic loci with small effects culminate in illness. We narrowed down our patient selection criteria to male Caucasian patients to reduce variations caused by ethnicity and gender. In addition, we chose patients who required clozapine treatment to further narrow down the patient group to those with more severe, chronic cases of the disease ([Supplementary Figure 1a](#SD1){ref-type="supplementary-material"}). All reprogrammed iPSCs showed hPSC-like morphology and expressed hPSC markers ([Fig. 1a](#F1){ref-type="fig"}).

We differentiated generated iPSCs into homogeneous populations of developmental cINs, using the protocol we optimized previously^[@R27],\ [@R28]^ with a slight modification ([Fig. 1b](#F1){ref-type="fig"}). This protocol efficiently generated a developmental cINs from multiple iPSC lines, as shown by immunocytochemistry where the majority of cells expressed the neuronal marker β-tubulin and the cIN markers SOX6 and GAD1 ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Figure 1b](#SD1){ref-type="supplementary-material"}). There was only a minimal number of neurons with alternate neuronal subtypes, such as dopaminergic neurons (TH^+^), serotonergic neurons (5HT^+^) and glutamatergic neurons (glutamate^+^) ([Fig. 1d](#F1){ref-type="fig"} and [Supplementary Figure 1c](#SD1){ref-type="supplementary-material"}).

Dysregulation of OxPhos genes in SCZ cINs {#S4}
-----------------------------------------

Having observed the induction of homogeneous populations of developmental cINs from multiple iPSCs, irrrespective of disease status, we began transcriptome analysis of these developmental cINs ([Supplementary Figure 2a](#SD1){ref-type="supplementary-material"}) to understand the intrinsic developmental abnormalities of SCZ cINs in the absence of other neuronal subtypes. In the initial pilot RNAseq we did, we used cINs from 9 HC and 9 SCZ subjects from a single differentiation per line ([Supplementary Figure 1a](#SD1){ref-type="supplementary-material"}). PCA analysis shows that generated cINs clustered with each other, clearly separated from the fibroblasts and iPSCs and from which they were sequentially derived ([Supplementary Figure 2b](#SD1){ref-type="supplementary-material"}). Whereas there was little expression of the pluripotent stem cell marker OCT4, astrocyte marker ALDH1L1, oligodendrocyte marker MBP or glutamatergic neuronal marker Vglut2, there was robust expression of the neuronal marker MAP2 and cIN marker genes, such as SOX6, GAD1, DLX2, VGAT and SST, regardless of disease status ([Fig. 2a](#F2){ref-type="fig"}), confirming the efficient generation of developmental cINs, as in the immunocytochemistry result.

Though the generated cINs displayed similar gene expression patterns overall ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}), Pathview analysis using whole transcriptome data showed that OxPhos was one of the most significantly affected pathways ([Fig. 2b](#F2){ref-type="fig"}. *p*=4.28e-8, *q*=7.03e-6). Among various mitochondrial complexes, the changes in mitochondrially encoded NADH dehydrogenases (complex I) were most pronounced ([Supplementary Figure 2c](#SD1){ref-type="supplementary-material"}). The most significant of these were ND2 and ND4L ([Fig. 2c](#F2){ref-type="fig"}), whose decreased expression was also confirmed by real time PCR analysis ([Fig. 2d](#F2){ref-type="fig"}). Next, we tested whether this abnormality in OxPhos gene expression was also observed in glutamatergic neurons. For this purpose, we differentiated iPSCs into induced postmitotic glutamatergic neurons by directly reprogramming them, using transient forced expression of NGN2^[@R50],\ [@R51]^. We analyzed their gene expression patterns two weeks after differentiation, when they are fully postmitotic neurons^[@R50],\ [@R51]^ ([Fig. 2e](#F2){ref-type="fig"}). Using this protocol, we could efficiently generate glutamatergic neurons from multiple iPSC lines, regardless of disease status ([Fig. 2f](#F2){ref-type="fig"}). There were few other neuronal subtypes, such as dopaminergic (TH^+^), serotonergic (5HT^+^) or GABAergic (GAD^+^) neurons present, demonstrating the homogeneity of the generated glutamatergic neurons ([Supplementary Figure 3a](#SD1){ref-type="supplementary-material"}). Efficient generation of glutamatergic neurons was also confirmed by RNAseq analysis, which showed negligible expression levels of non-relevant markers (pluripotent stem cell markers and other neural lineage markers) and enriched expression of mature glutamatergic neuronal markers ([Supplementary Figure 3b](#SD1){ref-type="supplementary-material"}). Unlike SCZ cINs, neither the expression of ND2 nor ND4L was significantly changed in SCZ glutamatergic neurons compared to HC glutamatergic neurons ([Fig. 2g](#F2){ref-type="fig"}), suggesting that homogeneous populations of neuronal subtypes are needed to tease apart cell specific SCZ pathogenetic mechanisms.

Considering the overall mild phenotypic changes in SCZ cINs, it is critical to test whether the initial results replicate in a larger sample set. Thus, we extended our RNAseq analysis to 15 HC and 15 SCZ lines, with additional independent differentiations (two independent differentiations per line, [Fig. 3a](#F3){ref-type="fig"}). Additional iPSC lines' phenotype and differentiation efficiency was confirmed in [Supplementary Figure 4a](#SD1){ref-type="supplementary-material"}--[b](#SD1){ref-type="supplementary-material"} and in our previous study^[@R48]^. As in the pilot RNAseq, PCA analysis showed that generated cINs clustered with each other, separated from the iPSCs and fibroblasts from which they were derived ([Supplementary Figure 4c](#SD1){ref-type="supplementary-material"}). The overall downregulation of mitochondrially encoded complex I gene expression was also observed in this expanded cohort ([Supplementary Figure 4d](#SD1){ref-type="supplementary-material"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). In addition to ND2 and ND4L, ND5 was significantly downregulated. These results were confirmed by real time PCR analysis ([Fig. 3b](#F3){ref-type="fig"}). However, we did not observe downregulation of OxPhos genes in the larger cohort of SCZ glutamatergic neurons ([Fig. 3b](#F3){ref-type="fig"}). We tested for over-representation of OxPhos genes among SCZ DE genes using Fisher's Exact test and observed significant enrichment of the OxPhos genes' among SCZ cIN DE genes (*p*=1.604e-11), but not in SCZ glutamatergic neurons (*p*\>0.999).

In addition to OxPhos enzymes, several other OxPhos-related genes were also altered in SCZ cINs. These genes include NSUN3, SLC25A15, AGO3 and FOSL2 ([Fig 3c](#F3){ref-type="fig"}). NSUN3, a mitochondrial tRNA methyltransferase, promotes mitochondrial activity^[@R52],\ [@R53]^. SLC25A15, a mitochondrial ornithine transporter, is critical for normal mitochondrial function^[@R54]^. AGO3, a core component of RNA induced silencing complexes (RISCs), regulates mitochondrial function by gene silencing^[@R55],\ [@R56]^. FOSL2, a component of the AP-1 transcription factor, participates in mitochondrial regulation of transcription^[@R57],\ [@R58]^. Dysregulation of these genes in SCZ cINs was confirmed by real time PCR analysis ([Fig. 3c](#F3){ref-type="fig"}), but were not observed in SCZ glutamatergic neurons ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Figure 3c](#SD1){ref-type="supplementary-material"}). Interestingly, some of the OxPhos DE genes were also significantly dysregulated in SCZ postmortem studies ([Supplementary Table 2](#SD2){ref-type="supplementary-material"} and [Table 3](#SD2){ref-type="supplementary-material"}) suggesting that iPSC-derived developing cINs already harbor some of signatures of SCZ neurons in adult brains.

Dysregulations of OxPhos enzymes and regulators in SCZ cINs are associated with mitochondrial functional deficits in cINs {#S5}
-------------------------------------------------------------------------------------------------------------------------

Having observed mild but significant dysregulation of multiple OxPhos genes, we sought to test whether observed mild dysregulation of multiple OxPhos genes did indeed result in a functional deficit in cIN mitochondria. Thus, we characterized the OxPhos functions of HC vs SCZ cINs using a Seahorse Analyzer. SZ derived cINs had significant decreases in maximal respiration ([Fig. 4a](#F4){ref-type="fig"}) and reserve capacity ([Fig. 4a](#F4){ref-type="fig"}), as defined in Materials and Methods section. Accordingly, when we assayed NAD level in HC vs SCZ cINs, a significant decrease of total NAD levels was observed ([Fig. 4b](#F4){ref-type="fig"}), though there is a caveat that reduction in cellular NAD level is not necessarily a direct indicator of mitochondrial NAD level. Mild but significant decreases in mitochondrial function resulted in a significant increase in Oxidative stress in SCZ cINs as assayed by Dichlorofluorescein (DCF) ([Fig. 4c](#F4){ref-type="fig"}), a membrane permeable dye that fluoresces upon oxidization by reactive oxygen species (ROS) in treated cells^[@R59]^. On the other hand, we did not observe any functional deficit of mitochondria in SCZ glutamatergic neurons ([Fig. 4d](#F4){ref-type="fig"}), consistent with the unaffected OxPhos gene expression in these neurons.

Reversal of SCZ cIN-specific deficits by chemical treatment {#S6}
-----------------------------------------------------------

There have been reports of chemicals that boost mitochondrial function, and we tested whether these compounds could reverse the deficit observed in SCZ cINs. We treated cINs with chemicals previously linked to the enhancement of mitochondrial function, including ALA/ALC^[@R60]--[@R62]^, [Omega-3 fatty acid](https://academic.oup.com/advances/article/3/1/¼557081)s^[@R63]--[@R66]^, CoQ10 (Coenzyme Q10)^[@R67],\ [@R68]^, NAc ([N-Acetyl cysteine](https://www.webmd.com/vitamins/ai/ingredientmono-1018/n-acetyl-cysteine))^[@R69],\ [@R70]^, or α-tocopherol^[@R71]^ after 8 weeks' differentiation and analyzed their mitochondrial function using the Seahorse analyzer after 24 hours' treatment. No chemical significantly altered OxPhos in HC cINs ([Fig. 5a](#F5){ref-type="fig"}). ALA/ALC significantly increased OxPhos in SCZ cINs, shown by significant increases in maximal respiration and reserve capacity ([Fig. 5a](#F5){ref-type="fig"}), whereas all other chemicals tested did not affect OxPhos in SCZ cINs. Since we previously observed SCZ cIN-specific deficits in arborization^[@R48]^, a process that requires active energy consumption^[@R29],\ [@R31]^, we tested whether the reversal of OxPhos deficits by ALA/ALC treatment could help ameliorate arborization deficits. Thus, we treated 8 weeks-old HC vs. SCZ cINs infected with a limiting titer of LV-Ubc-GFP with ALA/ALC for 7 days and analyzed their arborization. Consistent with the previous study, we observed a mild but significant decrease in arborization in SCZ cINs compared to HC cINs ([Supplementary Figure 5b](#SD1){ref-type="supplementary-material"}). ALA/ALC treatment ameliorated arborization deficits in SCZ cINs, but there was no significant effect in HC cINs ([Fig. 5b](#F5){ref-type="fig"}). This suggests that reversal of OxPhos deficits in SCZ cINs can ameliorate other energy consumption-related SCZ deficits, indicating that restoration of dysregulated mitochondrial function in cINs could be a valuable therapeutic target of SCZ.

Discussion {#S7}
==========

In this study, by employing homogeneous populations of developing SCZ cINs, we could identify OxPhos dysfunction as a major intrinsic abnormality in these cells during early development. Interestingly, a significant deficit was observed in reserve capacity and maximal respiration without a significant change in basal respiration in SCZ cINs, suggesting that SCZ cINs may not respond to stressful environments as effectively as HC cINs. There have been postmortem studies that reported abnormal mitochondrial function in various regions in SCZ patient brains^[@R9],\ [@R72]--[@R76]^. However, due to side effects of antipsychotics on mitochondrial function^[@R77]^, it has not been clear whether the OxPhos deficits observed in postmortem SCZ brains were SCZ-innate abnormalities or the side effect of drug treatment. This point was successfully addressed in our study using developmental cINs in the absence of any antipsychotics.

We observed OxPhos deficits were associated with oxidative stress in developing cINs. Interestingly, oxidative stress in SCZ cINs has been consistently observed in post-mortem tissues^[@R78]--[@R80]^ which could have been resulted from intrinsic abnormalities or could be resulted from other circuit-based abnormalities such as lower input from glutamatergic neurons. Our results demonstrate that oxidative stress can result from cIN-intrinsic OxPhos abnormalities in the absence of any circuit environment. Furthermore, we observed that arborization deficits in developmental cINs^[@R48]^, like OxPhos deficits, was reversed by ALA/ALC, suggesting that regulation of cIN OxPhos deficits could serve as a new therapeutic intervention to reverse cIN-related SCZ symptoms. Considering that mitochondria function is critical for proper neuronal functions^[@R29]--[@R38],\ [@R81]^ (including redox regulation^[@R81]^ and proper arborization^[@R31],\ [@R32]^), it is conceivable that mitochondrial dysfunction in cINs will result in suboptimal neuronal function. For example, defects in regulating inhibition of local circuitry could cause compromised circuit function, such as abnormal gamma oscillation, in which cINs play a critical role, and which is abnormal in SCZ patients^[@R25],\ [@R43]^. Interestingly, a recent study observed restoration of mitochondrial function, accompanied by reversal of SCZ-like behavioral deficits, by transplanting healthy mitochondria in a rat model of SCZ^[@R82]^.

Unlike metabolic disorders where more severe systemic symptoms are observed^[@R83],\ [@R84]^, SCZ cINs displayed modest decreases in OxPhos gene expression accompanied by modest reductions in mitochondrial function, which is consistent with the overall modest pathophysiology of SCZ. We observed that expression of many complex I genes was decreased in SCZ cINs, as was that of other mitochondria-related genes, including a mitochondrial tRNA methyltransferase (NSUN3), a mitochondrial carrier (SLC25A15), a RISC component (AGO3), and a transcriptional regulator (FOSL2). Thus, it seems that modest decreases of expression of many genes, each of which might not have impacted overall function of mitochondria much, collectively contributed to the reduction of mitochondrial function, in line with the multigenic nature of SCZ pathogenesis.

We have screened a small number of chemicals reported to have enhanced mitochondrial function in various cellular contexts and observed that an ALC/ALA combination significantly restored OxPhos in SCZ cINs. ALC is present in the brain at high concentrations and enhances mitochondrial function and energy production^[@R47]^. ALA has been used together with ALC to improve mitochondrial function^[@R62]^ and reduce the possible oxidative stress of ALC^[@R85]^. For potential clinical applications, ALA/ALC can easily cross the blood-brain barrier^[@R60],\ [@R86]^ and shows low side effects^[@R87]^, thus having the potential to be used as a safe adjuvant therapy for SCZ. All chemicals tested are known to boost mitochondrial function and are potent anti-oxidants, but ALA/ALC has unique mechanisms such as its role as an essential cofactor of mitochondrial enzymes^[@R46],\ [@R62],\ [@R88],\ [@R89]^, chelating potentially toxic metal ions such as Cu^2+^, Zn^2+^, Pb^2+^, Hg^2+^ and Fe^3+\ [@R90]^, and transporting long chain fatty acid into mitochondria, facilitating fatty acid beta-oxidation^[@R91]--[@R93]^. Further studies will reveal which of the mechanisms of action is responsible for the specificity of ALA/ALC in modifying SCZ cIN abnormalities.

Though there were no previous studies that examined OxPhos changes in developing SCZ cINs, there have been studies that examined mitochondrial function of other neural subtypes derived from patient iPSCs. The results of these studies showed varying aspects and degrees of changes depending on the different neural subtypes and differentiation stages^[@R94]--[@R96]^. Considering these context-dependent differences in OxPhos abnormalities, it is likely that we would not have been able to determine tissue specific abnormalities without using a homogeneous population of progenies, especially for cIN populations which comprise a minority of generated neurons in the absence of specific induction procedures using developmentally relevant signaling pathways, as used in our current protocol.

Recent large-scale efforts by the second set of Psychiatric Genomics Consortium (PGC2) identified more than 100 SCZ risk loci with genome-wide significance (*p*\<5×10^−8^)^[@R97]^. Interestingly, among \>300 putative SCZ risk genes within these loci, there was significant enrichment of mitochondrial genes (total 22 genes, *p*\<0.05 by hypergeometric test)^[@R76],\ [@R98]^, pointing to the potential role of mitochondrial abnormality in SCZ pathogenesis. We did not find any overlap between our OxPhos DE genes and these putative SCZ risk genes from PGC2, but it will be interesting to examine the much larger putative SCZ risk gene list that will be released from PGC3 for this purpose^[@R99]^.

Homogeneous populations of developmental cINs used in this study allowed us to observe cIN intrinsic transcriptome abnormalities in OxPhos gene expression, with corroborating mitochondria hypofunctions from SCZ cINs during early development. These observations were not a result of antipsychotic treatment and were confirmed in the absence of other neuronal subtypes that can affect the functionality of cINs, revealing what is inherent to these SCZ cINs. The OxPhox abnormalities in these cINs could be reversed by one of the chemical treatments reported to enhance mitochondrial function, accompanied by restoration of other downstream abnormalities, specifically, abnormal arborization. The results demonstrate the promise of studying homogeneous disease relevant cell populations to dissect aspects of SCZ pathogenetic mechanisms. Some of these abnormalities, which would not be detected in mixed cell populations, could provide novel potential target to treat or even prevent SCZ.

Materials and methods {#S8}
=====================

Generation of induced pluripotent stem cells {#S9}
--------------------------------------------

These study protocols were approved by the McLean Hospital/Partners Healthcare Institutional Review Board and New York Medical College Institutional Review Board. All procedures were performed in accordance with the Institutional Review Board's guidelines and all human samples were obtained with informed consent. Human fibroblasts were obtained from Dr. Bruce Cohen (McLean Hospital), Dr. Daniel Weinberger (Lieber Institute for Brain Development), and Dr. Judith Rapoport (National Institute of Mental Health). Skin biopsies were performed on healthy donors and SCZ patients. The skin tissue cut out one or two 4mm cylindrical pieces of skin. They were performed under local anesthesia (2% Lidocaine with or without epinephrine). The skin samples were washed with PBS 3 times and placed in 35mm culture dishes. One drop of DMEM with Glutamax with 10% fetal bovine serum (FBS), 2% L-Glutamine, 1% Penicillin/Streptomycin solution (PS), and 1% Amphotericin and Gentamicin solution was added on each piece of skin and put in an incubator (37°C/5% CO^2^). The skin samples in the culture dishes were changed with fresh media every other day to induce fibroblast cell growth as described in^[@R100]^.

Human fibroblasts were reprogrammed using modified RNA methods^[@R49]^ by Cellular Reprogramming, Inc. (San Diego, CA). Each fibroblast line was plated to 6-well plates without feeders at three different plating densities and subjected to messenger RNA reprogramming. Nascent colonies were bulk-passaged from the most productive well to establish passage 1 (P1) iPSC cultures on rLaminin-521 (BioLamina, Sweden) in Nutristem XF media (Biological Industries, Israel) and expanded in the same culture system until at least passage 3 before being characterized by 4'-6-diamidino-2-phenylindole (DAPI)/OCT4/TRA-1--60 immunostaining and frozen down for storage.

Differentiation of iPSCs into cINs {#S10}
----------------------------------

Thawed human iPSCs were maintained on Matrigel (BD, San Jose, CA) coated plates with Essential 8 (E8) media (Invitrogen, Carlsbad, CA). ROCK inhibitor, Y27632 (10uM, ApexBio, Boston, MA, USA) was added to the culture for 24 hours after passaging to prevent single cell-induced cell death of iPSCs.

cINs are generated from MGE progenitors during embryonic development through the action of relevant signaling molecules. Thus, first we induced the MGE phenotype by ventralizing iPSC-derived neuroectoderm by SHH activation and WNT inhibition. More specifically, iPSCs were trypsinized and grown as floating spheres in low adherent flasks in KSR media (DMEM, 15 % knockout serum replacement, 2 mM L-glutamine and 10 μM β-mercaptoethanol (all from Invitrogen) from day 0 to day 14 with the phenotype-inducing chemical combinations as described below. Y27632 (10uM) was added to the culture on the first day of differentiation again to prevent single cell-induced cell death of iPSCs. For neuroectoderm induction, cells were treated with LDN193189 (100 nM, Stemgent, Cambridge, MA) from day 0 to day 14 and SB431542 (10 μM, Tocris Cookson, Ellisville, MO) from day 0 to day 7. For MGE phenotype induction, media was supplemented with IWP2 (5 μM, EMD Millipore, Billerica, MA) from day 0 to day 7 and SAG (0.1 μM, EMD Millipore) from d0 to d21. From day 14, cells were grown in N2AA media (DMEM-F12 with N2-supplement (1:200, Invitrogen) and 200 μM ascorbic acid (AA, Sigma, St. Louis, MO)). FGF8 (100 ng/ml, Peprotech, Rocky Hill, NJ) was added from day 14 to day 21 to induce MGE phenotype at the expense of the CGE phenotype^[@R27]^. iPSCs passaged to low adherent flasks rapidly form spheres and MGE phenotype induction with the above-described chemicals was carried out in these sphere cultures. After three weeks' induction as spheres, most of the cells take up the MGE phenotype, as we previously described in detail^[@R27]^. Induced MGE progenitors spontaneously differentiate and generate postmitotic cINs, as during their normal development, and thus once the MGE phenotype was established, we withdraw all morphogenic signaling molecules from the culture and then spontaneous differentiation proceeded as described below.

For differentiation into postmitotic cINs, we supplemented N2AA media with 10 ng/ml glial cell derived neurotrophic factor (GDNF, Peprotech) and 10 ng/ml brain derived neurotrophic factor (BDNF, Peprotech) from day 21 to provide trophic support for postmitotic cINs. At day 45 of differentiation, cIN spheres were trypsinized in the presence of 0.1M trehalose (Sigma) and the resuspended cells were filtered through a cell strainer cap (35μm nylon mesh, Corning, NY, USA) to exclude the dead cell cluster, and then plated on polyornithine (PLO; 15 mg/ml; Sigma) and fibronectin (FN; 1 mg/ml; Sigma)-coated plates in B27GB media (DMEM-F12 media with B27 supplement (1:100, Invitrogen), 10 ng/ml GDNF and 10 ng/ml BDNF) supplemented with 10uM Y27632 on the first day of passaging only. Cells were fixed for immunocytochemistry at 6w of differentiation and harvested for RNA preparation at 8w of differentiation. All cell lines are routinely tested for mycoplasma contamination using a Mycoplasma Detection Kit (InvivoGen, San Diego, CA, USA). Cell lines used in this study were verified to be mycoplasma free before undertaking any experiment with them. Cell lines used for each experiment are summarized in [Supplementary Table 5](#SD2){ref-type="supplementary-material"}.

Differentiation of iPSCs into Glutamatergic neurons {#S11}
---------------------------------------------------

Human iPSC cells were seeded at a density of 10^6^ cells/well on Matrigel-coated 6-well plates with E8 media and 5 μM Rock inhibitor Y-27632 (Selleck Chemicals, Houston, TX), a lentivirus that inducibly expresses Ngn2 and constitutively expresses the Puromycin resistance gene (packaged using pLV_TRET_hNgn2_UBC_Puro plasmid from Addgene, Plasmid \#61474 (Addgene, Cambridge, MA)), 2 μg/ml of Doxycycline and 2 μg/ml of polybrene. After overnight incubation (day 1), the media was replaced with N2AAGB media (DMEMF12 with N2 supplement (1:200), 200 μM ascorbic acid, 10 ng/ml GDNF and 10 ng/ml BDNF) with 2 μg/ml of Doxycycline. At day 2, 1 μg/ml of Puromycin was added to the culture. At day 3, the media was changed with B27GB media (DMEMF12 with B27 Supplement (1:100), 10 ng/ml GDNF and 10 ng/ml BDNF) and 2 μg/ml of Doxycycline and changed every other day until day 14. At day 14, the glutaminergic neurons were harvested for RNA preparation using Trizol or fixed with 4% paraformaldehyde (PFA).

Immunocytochemistry, Cell counting and Arborization analysis {#S12}
------------------------------------------------------------

Cells were fixed in 4% PFA for 10 min. The fixed cells were blocked in PBS with 10% normal serum and 0.1% Triton X-100 for 10 min at room temperature (RT). Cells were incubated with the primary antibody in PBS with 2% normal serum overnight at 4°C. After washing in PBS, the cells were incubated with the fluorescently-labeled secondary antibody in PBS with 2% normal serum for 1 hour at RT. Cell nuclei were also counterstained with DAPI (Invitrogen, 1:10,000). The antibodies used are summarized in [Supplementary Table 6](#SD2){ref-type="supplementary-material"}. After washing in PBS, coverslips were mounted onto slide glass using Fluoromount-G (Southern Biotech, Birmingham, AL). Fluorescent images were taken using the EVOS FL Auto microscope (Life Technologies, Carlsbad, CA) or Olympus DSU Spinning Disc Confocal on an IX81 inverted microscope (Olympus, Center Valley, PA).

For cell counting, Image J software (Version 1.51p, NIH, Bethesda, MD) was used to count the cell number using the multi point function. Percentages of cells positive for each marker were quantified in relation to DAPI-stained nuclei from three independent differentiations. At least 500 cells were counted for each line.

For arborization analysis, cells were infected with a limiting concentration of LV-UbiC-GFP virus (MOI=0.001) to induce scarce infections, treated with different chemicals in B27GB media for 7 days and fixed for analysis. GFP^+^ cells were traced using ImageJ software version 1.51 (NIH) with the NeuronJ plug in to obtain parameters of arborization such as neurite length, neurite number from soma, and branch number.

RNA preparation and Real time PCR {#S13}
---------------------------------

RNA samples were isolated using a TRIzol-reagent (Invitrogen) and 300ng of the total RNA was used for cDNA synthesis using the Oligo(dT)~12--18~ primer (Gene Link, Hawthorne, NY), 0.5 mM dNTP mix (Thermo Scientific, Waltham, MA), 5 mM DTT (Invitrogen), RevertAid H minus RT (Thermo Scientific), and 5× Reaction Buffer (Thermo Scientific) in SimpliAmp™ Thermal Cycler (Applied Biosystems, Waltham, MA). The real time PCRs were performed using the CFX Connect™ Real-Time PCR Detection System (BioRad, Hercules, CA), with 40 cycles of denaturation (95°C for 15sec), annealing (55°C for 30sec), and extension (72°C for 30sec). The primer sequences used for real time PCR are summarized in [Supplementary Table 7](#SD2){ref-type="supplementary-material"}.

RNA-seq Analysis {#S14}
----------------

For the RNAseq analysis, RNA quality was examined by the 4200 TapeStation (Agilent Technologies, Santa Clara, CA) and RNA concentration was determined by the Qubit Fluorometric Quantitation (Life Technologies, Carlsbad, CA). For each sample, 100--200ng of RNA was used to construct a cDNA sequencing library using the TruSeq Stranded mRNA Library Preparation Kit (Illumina, San Diego, CA), in accordance with the protocol using the poly-adenylated RNA isolation. Paired-end sequencing (75 bp × 2) was performed in the Illumina NextSeq 550 system. Raw sequence reads were de-multiplexed and trimmed for adapters by using the Illumina bcl2fastq conversion software (v2.19). Sequence reads of each sample were pseudo-aligned to human hg38 reference transcriptome and the gene transcript abundance was quantified by using Kallisto^[@R101]^. Pathway analysis was performed by GAGE and Pathview packages^[@R102]^ using whole transcriptome data. The differential expression of genes and transcripts were achieved in paired groups by using tximport and DESeq2 packages^[@R103]^ in R platform. The RNA-Seq data are available at the GEO website (<https://www.ncbi.nlm.nih.gov/geo/>) under accession GSE125805 and GSE GSE125999.

Mitochondria-related gene list ([Supplementary Table 8](#SD2){ref-type="supplementary-material"}) were generated by combining mitochondria-related gene sets from the KEGG OxPhos pathway gene set^[@R104]^, the MitoCarta mitochondrially expressed gene set^[@R105]^, nucleus-mitochondria crosstalk gene sets^[@R106]--[@R109]^ as well as genes with high PubMed hit numbers with OxPhos search terms (\>10 hits). After removing duplicate genes among these gene sets, a total of 1308 mitochondria-related genes were used as a reference gene set for Fisher's exact test and for OxPhos annotation of DE genes. For the enrichment analyses of OxPhos genes for cINs and glutamatergic neurons, a one-sided Fisher's exact test was used to test the over-representation (enrichment) using R statistical software (version 3.5.1, <http://www.R-project.org/>).

Chemical preparation and storage {#S15}
--------------------------------

All chemicals were obtained from Sigma (St. Louis, MO). α-lipoic acid (ALA) was dissolved in pure ethanol to make a 50mM stock. acetyl-L-carnitine (ALC) was dissolved in phosphate buffer saline (PBS) to make a 10mM stock. cis-5,8,11,14,17-Eicosapentaenoic acid (EPA) and cis-4,7,10,13,16,19-Docosahexaenoic acid (DHA) were dissolved in pure ethanol to make 50mM stocks. Coenzyme Q10 (CoQ10) was dissolved in DMSO to make a 30mM stock. N-Acetyl-L-cysteine (NAC) was dissolved in pure ethanol to make a 100mM stock. α-tocopherol (α-TCP) was dissolved in pure ethanol to make a 50mM stock. All stocks were aliquoted and stored at −20°C to avoid repeated freezing and thawing. All chemicals were diluted by 1:1000 in the culture media and used for cell culture.

OxPhos analysis using Seahorse analyzer {#S16}
---------------------------------------

Mitochondrial activity of cINs was measured using the Seahorse XFp8 analyzer (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. Briefly, 2e5 cells were plated in the XF cell culture miniplate and incubated at 37°C with 5% CO~2~. One day before the test, the cartridge with XF calibrant was incubated in a non-CO~2~ incubator overnight to equilibrate. Before the assay, the media was changed to the XF assay medium supplemented with 5 mM sodium pyruvate (Thermo Scientific, Waltham, MA), 10 mM glucose (Thermo Scientific, Waltham, MA), and 2 mM glutamine, and equilibrated in a non-CO~2~ incubator for 1 hour. Oxygen consumption rate (OCR) were monitored through sequential injections of 1 μM oligomycin, 0.3 μM FCCP and 1 μM rotenone/antimycin A (Seahorse XF Cell Mito Stress Test Kit, Agilent, Santa Clara, CA). The various parameters of the mitochondrial activity were calculated as illustrated in [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}: Basal Respiration=baseline OCR-Rotenone/antimycin A OCR, ATP production=Baseline OCR-Oligomycin OCR, Maximum Respiration=FCCP OCR-Rotenone/antimycin A OCR and Space Capacity=Maximum Respiration-Basal Respiration. Following analysis, plates were washed with PBS a couple of times to remove dead cells or cell debris before lysing cells. The result was normalized to total protein levels quantified using a BCA protein assay (Thermo Scientific, Cambridge, MA).

Cellular total NAD content assay {#S17}
--------------------------------

Cellular total NAD content of cINs was measured using an NAD/NADH cell-based assay kit (Cayman chemical, Ann Arbor, MI) according to the manufacturer's instructions. Briefly, cells were plated in a clear 96-well plate and incubated at 37°C with 5% CO~2~. The cells were washed with assay buffer, followed by the addition of the prepared permeabilization buffer and incubation with gentle shaking for 30min at room temperature. The permeabilization buffer from each well was transferred to a new well in a new 96-well plate, along with prepared standard samples for the standard curve. Reaction buffer was added to each well and the cells were incubated with gentle shaking for 90min at room temperature. The absorbance of each sample was then calculated using a microplate reader at a wavelength of 450nm, and the total NAD content was calculated using the standard curve.

Cellular Oxidative stress assay using DCF {#S18}
-----------------------------------------

Cells were plated in a clear 96-well plate and incubated at 37°C with 5% CO~2~. DCFDA Cellular Reactive Oxygen Species Detection Assay Kit was used to test the cellular oxidative stress level. Stock DCF reagent was diluted using PBS (final working concentration is 1 μM) and added to each well. After 30min incubation in 37 °C, the fluorescence signal was read using a microplate reader of 485nm/529nm.

Statistical analysis {#S19}
--------------------

All statistical analyses were performed using GraphPad Prism7 (GraphPad Software, La Jolla CA) and SPSS (version 16; SPSS Inc., Chicago, IL). The normal distribution of data was tested using the Shapiro-Wilks test and when significant, log-transformed data were used for comparison or alternatively, a nonparametric Kolmogorov-Smirnov test was used for comparison. We tested equal variance by the F-test or Levine's test and if there was a significant difference, we used a t-test with Welch's correction. A two-tailed unpaired t-test was used to compare the means between two groups when the assumptions of normal distribution and equal variance were met. When comparing more than 2 groups, a one-way ANOVA was used. For comparison of OCR after chemical treatment, mixed effect model were used to handle clustering and covariance among correlated samples^[@R110],\ [@R111]^. Dunnett's test was used to compare each of groups with a control group as a post hoc analysis with an adjustment for multiple comparisons. P-values \<0.05 were considered to be statistically significant.

No statistical method was used to pre-determine the sample sizes. However, the sample size we used in this study is similar to the largest sample among previous publications. This sample size was adequate to identify the dysfunction of Oxidative Phosphorylation in schizophrenia interneurons. No data were excluded. Experimental cohorts were chosen based on our selection criteria (Caucasian male patients treated with Clozapine vs. age- and gender-matched Caucasian male healthy controls) without randomization to reduce variation caused by age, ethnicity and gender. Blinding was used during cell counting and arborization analysis. For each figure, the statistical test was justified as appropriate, meeting the assumption of the tests as summarized in [Supplementary Table 9](#SD2){ref-type="supplementary-material"}.

Supplementary Material {#SM1}
======================

###### 

**Supplementary Figure 1. Generation of homogeneous populations of cINs from HC and SCZ iPSCs.** *Related to* [Fig. 1](#F1){ref-type="fig"}.

\(a\) Table of subjects analyzed in pilot study. HC refers to healthy control subjects and SCZ refers to schizophrenia patients.

\(b\) Cell counting analysis of generated cINs for expression of Sox6, GAD1 and β-Tubulin, analyzed after 8 weeks' differentiation. Data is presented as mean±SEM from three independent differentiations. There was no significant difference among lines by one-way ANOVA (SOX6, p=0.531; GAD1, p=0.123; β-Tubulin, p=0.318).

\(c\) Cell counting analysis of generated cINs for expression of TH, 5-HT, Glutamate and GAD1, analyzed after 8 weeks' differentiation. Data is presented as mean±SEM from three independent differentiations. There was no significant difference among lines by two-tailed unpaired t-test (TH, p=0.967; 5-HT, p=0.781; Glutamate, p=1.000; GAD1, p=0.089).

**Supplementary Figure 2. RNAseq Analysis of HC vs SCZ cINs.** *Related to* [Fig. 2](#F2){ref-type="fig"}.

\(a\) Number of reads generated. Rate (%) = Read number of Pseudoaligned/Read number of Input×100.

\(b\) Principal component analysis of HC and SCZ cINs. RNA-seq data of iPSC and fibroblasts were from Choi et al. (Choi J, Lee S, Mallard W, Clement K, Tagliazucchi GM, Lim H *et al.* A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. *Nature biotechnology* 2015; **33**(11): 1173--1181).

\(c\) Heat map depicting expression changes of mitochondrial Complex I in SCZ cINs. The color in each box corresponds to the value of Log2Fold Changes (Log2FC) for each gene. Blue color indicates down-regulation in SCZ cINs and red color indicates up-regulation in SCZ cINs. The scale bar on the right shows the color of designated Log2Fold Changes values.

**Supplementary Figure 3. Generation of homogeneous population of glutamatergic neurons from HC vs. SCZ iPSCs.** *Related to* [Fig. 2](#F2){ref-type="fig"}.

\(a\) Immunocytochemistry analysis of induced glutaminergic neurons for Brn2, TH, 5-HT and GAD1 expression. Scale bar=100 μm.

(b-c) RNAseq transcriptome profiling of NGN2-induced glutaminergic neurons derived from 5 HC iPSCs vs. 5 SCZ iPSCs. Gene expression is shown as transcripts per million (TPM). Differential expression was analyzed by DESeq2. Error bars are SEM.

**Supplementary Figure 4. RNAseq Analysis of HC vs SCZ cINs in a larger cohort.** *Related to* [Fig. 3](#F3){ref-type="fig"}.

\(a\) Immunocytochemistry analysis of iPSCs for expression of human PSC markers, Oct4 and Tra-1--60. Scale bar=200μm.

\(b\) Cell counting analysis of generated cINs for expression of Sox6, GAD1 and β-Tubulin, analyzed after 8 weeks' differentiation. Data is presented as mean±SEM from three independent differentiations. There was no significant difference among lines by one-way ANOVA (SOX6, p=0.714; GAD1, p=0.479; β-Tubulin, p=0.490).

\(c\) Principal component analysis of HC and SCZ cINs. RNA-seq data of iPSC and fibroblasts were from Choi et al. (Choi J, Lee S, Mallard W, Clement K, Tagliazucchi GM, Lim H *et al.* A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. *Nature biotechnology* 2015; **33**(11): 1173--1181).

\(d\) Heat map depicting expression changes of mitochondrial Complex I in SCZ cINs. The color in each box corresponds to the value of Log2Fold Changes (Log2FC) for each gene. Blue color indicates down-regulation in SCZ cINs and red color indicates up-regulation in SCZ cINs. The scale bar on the right shows the color of designated Log2Fold Changes value.

**Supplementary Figure 5. Arborization analysis of HC and SCZ cINs with and without ALA/ALC treatment.** *Related to* [Fig. 5](#F5){ref-type="fig"}.

\(a\) Tracing of ALA/ALC-treated HC or SCZ cINs (Scale bar=50 μm).

\(b\) Arborization deficits in SCZ cINs compared with HC cINs. cINs infected with a limiting titer of GFP-expressing lentivirus were analyzed using ImageJ with the Neuron J plugin. Data are presented as mean±SEM. Two-tailed unpaired t-test was used for analysis (HC: n= 40 neurons per group).
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![Generation of homogeneous population of developmental cINs from HC and SCZ iPSCs\
(a) Immunocytochemistry analysis of generated iPSCs for expression of human PSC markers, Oct4 and Tra-1--60. Scale bar=200μm.\
(b) Differentiation scheme of cINs from hPSCs. SRM: serum replacement media, LDN: 100 nM LDN193189, SB: 10 μM SB431542, SAG: 0.1 μM Smoothened agonist, and IWP2: 5 μM Inhibitor of Wnt production-2. After 8 weeks' differentiation, the cells were harvested for experiment.\
(c) Immunocytochemistry analysis of generated cINs for expression of Sox6, GAD1 and β-Tubulin, analyzed after 8 weeks' differentiation. Scale bar=50μm.\
(d) Immunocytochemistry analysis for TH, 5-HT and Glutamate, analyzed after 8 weeks' differentiation. Scale bar=50μm.](nihms-1526297-f0001){#F1}

![Oxidative phosphorylation pathway is significantly altered in developing SCZ cINs, but not in SCZ glutamatergic neurons.\
(a) RNAseq transcriptome profiling of cINs derived from 9 HC iPSCs vs. 9 SCZ iPSCs. Gene expression is shown as transcripts per kilobase million (TPM). Differential expression was analyzed by DESeq (n=9 RNAseq). Error bars are SEM.\
(b) Pathway analysis of enriched genes with differential expression using GAGE and Pathview in R and KEGG database. *q* value: *p* value with multiple testing correction.\
(c) ND2 and ND4L expression in 9 HC vs 9 SCZ cINs, analyzed by RNAseq. Gene expression is shown as transcripts per million (TPM). Differential expression was analyzed by DESeq2 (n=9 RNAseq). Error bars are SEM.\
(d) Quantitative real-time PCR analysis of ND2 and ND4L mRNA expression in 9 HC vs 9 SCZ cINs. Data were normalized by GAPDH expression and are presented as mean±SEM. Two-tailed unpaired t-test was used for analysis (n=9 lines).\
(e) The differentiation scheme of glutaminergic neurons. iPSCs were infected with LV-TetO-Ngn2-puro, and Ngn2 expression was induced by doxycyclin for 10 days. Induced glutamatergic neurons were harvested after 14 days' differentiation for analysis.\
(f) Immunocytochemistry analysis of induced glutaminergic neurons with anti-Glutamate antibodies. Scale bar=20 μm.\
(g) Quantitative real-time PCR analysis of ND2 and ND4L mRNA expression in HC and SCZ glutaminergic neurons. Data were normalized by GAPDH gene expression and are presented as mean±SEM. Two-tailed unpaired t-test was used for analysis (n= 6 lines).](nihms-1526297-f0002){#F2}

![Multiple OxPhos genes are dysregulated in developing SCZ cINs in expanded cohort\
(a) Demographic information of subjects in the expanded cohort.\
(b-c) RNAseq transcriptome profiling and quantitative real-time PCR analysis of cINs derived from 15 HC vs. 15 SCZ iPSCs and glutamatergic neurons derived from 11 HC vs. 11 SCZ iPSCs. For RNAseq, gene expression is shown as transcripts per million (TPM) and differentially expressed genes were analyzed by DESeq2. For real-tim PCR, data were normalized by GAPDH expression and analyzed using two-tailed unpaired t-test (n=15 lines per group, including two independent differentiations per line). Data are presented as mean±SEM.](nihms-1526297-f0003){#F3}

![Dysregulation of OxPhos genes in SCZ cINs resulted in defects in mitochondrial function.\
(a) Analysis of oxidative phosphorylation using Seahorse Analyzer, showing significant decrease in mitochondrial function in SCZ cINs. Data are presented as mean±SEM. Two-tailed unpaired t-test was used for analysis (n=11 lines per group, with two independent differentiations per line).\
(b) NAD assay in HC vs. SCZ cINs. Data are presented as mean±SEM. Two-tailed unpaired t-test was used for analysis (n=6 lines in HC group and 5 lines in SCZ group, with two independent differentiations per line).\
(c) Decreased mitochondrial function in SCZ cINs resulted in increased oxidative stress, assayed by DCF assay. Scale bar=20 μm. Data are presented as mean±SEM. Two-tailed unpaired t-test was used for analysis (n=6 lines in HC group and 4 lines in SCZ group, with two independent differentiations per line).\
(d) Analysis of oxidative phosphorylation using Seahorse Analyzer, showing no significant change in mitochondrial function in SCZ glutamatergic neurons. Data are presented as mean±SEM. Two-tailed unpaired t-test was used for analysis (n=3 lines per group).](nihms-1526297-f0004){#F4}

![Reversal of OxPhos deficits with chemical treatment.\
(a) Screening of chemicals that reverse OxPhos deficits in SCZ cINs using Seahorse Analyzer. Top black graphs are analysis in HC lines and bottom red graphs are analysis SCZ lines. Con: no treatment control. ALA/ALC: Alpha Lipoic Acid/Acetyl-L-Carnitine; [Omega-3](https://academic.oup.com/advances/article/3/1/¼557081): [Omega-3](https://academic.oup.com/advances/article/3/1/¼557081) fatty acids (DHA+EPA+ALA); CoQ10: Coenzyme Q10; NAc: N-acetylcysteine; α-TCP: α-tocopherol. Data are presented as mean±SEM. Paired one-way ANOVA test was used for analysis (n=4 lines per group with two independent differentiations per line), followed by Dunnett post-hoc analysis ([supplementary Table 4](#SD2){ref-type="supplementary-material"}).\
(b) ALA/ALC ameliorate arborization deficits in SCZ cINs. cINs infected with a limiting titer of GFP-expressing lentivirus were treated with ALA/ALC for 7 days and analyzed using ImageJ with the Neuron J plugin. Scale bar=20 μm. Data are presented as mean±SEM. Two-tailed unpaired t-test was used for analysis (HC: n= 40 neurons).](nihms-1526297-f0005){#F5}
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